39000411|t|The Effect of Neuropsychiatric Drugs on the Oxidation-Reduction Balance in Therapy.
39000411|a|The effectiveness of available neuropsychiatric drugs in the era of an increasing number of patients is not sufficient, and the complexity of neuropsychiatric disease entities that are difficult to diagnose and therapeutically is increasing. Also, discoveries about the pathophysiology of neuropsychiatric diseases are promising, including those initiating a new round of innovations in the role of oxidative stress in the etiology of neuropsychiatric diseases. Oxidative stress is highly related to mental disorders, in the treatment of which the most frequently used are first- and second-generation antipsychotics, mood stabilizers, and antidepressants. Literature reports on the effect of neuropsychiatric drugs on oxidative stress are divergent. They are starting with those proving their protective effect and ending with those confirming disturbances in the oxidation-reduction balance. The presented publication reviews the state of knowledge on the role of oxidative stress in the most frequently used therapies for neuropsychiatric diseases using first- and second-generation antipsychotic drugs, i.e., haloperidol, clozapine, risperidone, olanzapine, quetiapine, or aripiprazole, mood stabilizers: lithium, carbamazepine, valproic acid, oxcarbazepine, and antidepressants: citalopram, sertraline, and venlafaxine, along with a brief pharmacological characteristic, preclinical and clinical studies effects.
39000411	14	36	Neuropsychiatric Drugs	Disease	MESH:D000081015
39000411	115	137	neuropsychiatric drugs	Disease	MESH:D000081015
39000411	176	184	patients	Species	9606
39000411	226	250	neuropsychiatric disease	Disease	MESH:D004194
39000411	373	398	neuropsychiatric diseases	Disease	MESH:D004194
39000411	519	544	neuropsychiatric diseases	Disease	MESH:D004194
39000411	584	600	mental disorders	Disease	MESH:D001523
39000411	707	718	stabilizers	Chemical	-
39000411	777	799	neuropsychiatric drugs	Disease	MESH:D000081015
39000411	1109	1134	neuropsychiatric diseases	Disease	MESH:D004194
39000411	1197	1208	haloperidol	Chemical	MESH:D006220
39000411	1210	1219	clozapine	Chemical	MESH:D003024
39000411	1221	1232	risperidone	Chemical	MESH:D018967
39000411	1234	1244	olanzapine	Chemical	MESH:D000077152
39000411	1246	1256	quetiapine	Chemical	MESH:D000069348
39000411	1261	1273	aripiprazole	Chemical	MESH:D000068180
39000411	1280	1291	stabilizers	Chemical	-
39000411	1293	1300	lithium	Chemical	MESH:D008094
39000411	1302	1315	carbamazepine	Chemical	MESH:D002220
39000411	1317	1330	valproic acid	Chemical	MESH:D014635
39000411	1332	1345	oxcarbazepine	Chemical	MESH:D000078330
39000411	1368	1378	citalopram	Chemical	MESH:D015283
39000411	1380	1390	sertraline	Chemical	MESH:D020280
39000411	1396	1407	venlafaxine	Chemical	MESH:D000069470
39000411	Negative_Correlation	MESH:D002220	MESH:D004194
39000411	Negative_Correlation	MESH:D000069348	MESH:D004194
39000411	Negative_Correlation	MESH:D018967	MESH:D004194
39000411	Negative_Correlation	MESH:D000078330	MESH:D004194
39000411	Negative_Correlation	MESH:D020280	MESH:D004194
39000411	Negative_Correlation	MESH:D000069470	MESH:D004194
39000411	Negative_Correlation	MESH:D006220	MESH:D004194
39000411	Negative_Correlation	MESH:D008094	MESH:D004194
39000411	Negative_Correlation	MESH:D003024	MESH:D004194
39000411	Negative_Correlation	MESH:D000068180	MESH:D004194
39000411	Negative_Correlation	MESH:D014635	MESH:D004194
39000411	Negative_Correlation	MESH:D000077152	MESH:D004194

